Amundi Purchases 10,168 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Amundi raised its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 188.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 15,568 shares of the specialty pharmaceutical company's stock after purchasing an additional 10,168 shares during the quarter. Amundi's holdings in Collegium Pharmaceutical were worth $446,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of the stock. Principal Financial Group Inc. grew its holdings in Collegium Pharmaceutical by 3.9% during the third quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company's stock worth $67,459,000 after buying an additional 64,958 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Collegium Pharmaceutical by 0.7% during the 3rd quarter. Geode Capital Management LLC now owns 775,579 shares of the specialty pharmaceutical company's stock worth $29,974,000 after acquiring an additional 5,464 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Collegium Pharmaceutical by 17.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 765,692 shares of the specialty pharmaceutical company's stock worth $29,586,000 after acquiring an additional 116,327 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Collegium Pharmaceutical by 4.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 381,494 shares of the specialty pharmaceutical company's stock valued at $14,741,000 after purchasing an additional 16,655 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of Collegium Pharmaceutical by 173.6% during the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company's stock valued at $10,711,000 after purchasing an additional 175,892 shares in the last quarter.

Remove Ads

Collegium Pharmaceutical Stock Performance

Shares of Collegium Pharmaceutical stock traded up $0.51 on Monday, reaching $30.56. 556,260 shares of the company traded hands, compared to its average volume of 418,748. The company has a 50 day moving average of $30.69 and a 200 day moving average of $32.64. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. Collegium Pharmaceutical, Inc. has a 52 week low of $27.28 and a 52 week high of $42.29. The firm has a market capitalization of $962.21 million, a PE ratio of 13.17 and a beta of 0.99.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The business had revenue of $181.95 million during the quarter, compared to the consensus estimate of $179.68 million. Equities analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Needham & Company LLC raised shares of Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 price objective for the company in a research report on Friday, January 10th. Piper Sandler reduced their target price on Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating for the company in a report on Tuesday, February 4th. Finally, HC Wainwright reiterated a "buy" rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a report on Monday. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $43.60.

Insider Activity at Collegium Pharmaceutical

In other news, EVP Scott Dreyer sold 2,255 shares of the firm's stock in a transaction on Friday, March 14th. The stock was sold at an average price of $30.00, for a total value of $67,650.00. Following the completion of the transaction, the executive vice president now directly owns 124,421 shares of the company's stock, valued at $3,732,630. This trade represents a 1.78 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Colleen Tupper sold 977 shares of Collegium Pharmaceutical stock in a transaction on Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $29,310.00. Following the completion of the transaction, the chief financial officer now owns 164,269 shares of the company's stock, valued at approximately $4,928,070. This trade represents a 0.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 109,193 shares of company stock worth $3,243,594. Company insiders own 3.98% of the company's stock.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.